Axon's Past Rebounds Look Strong, but Today's Valuation Needs Cash Flow
Axon recovered after most historical 20% drops, but those episodes also brought deep interim losses. Current revenue growth remains exceptional, while a high sales multiple and weak recent free cash flow make history an incomplete guide.
Axon Enterprise fell 16.6% from September 22 through October 19, adding to a year in which the shares had already underperformed the broader market. A Trefis study found that Axon later traded higher in 14 of 19 earlier drawdowns that had a full one-year record, with a median 12-month gain of 58%.
That statistic is encouraging, but it does not describe a smooth recovery. Across the same episodes, the median lowest close during the following year was 15.2% below the initial dip price. Buyers also waited a median 285 calendar days for the best price in the next year. Past rebounds therefore came with substantial timing and drawdown risk.
The business is still expanding rapidly
Axon reported second-quarter revenue of $904 million, up 35% from a year earlier. Software and Services revenue increased 36% to $398 million, while Connected Devices revenue rose 35% to $507 million. Management credited products including Dedrone, TASER 10 and Axon Body 4 and raised full-year revenue growth guidance to 32% to 34%.
Annual recurring revenue reached $1.6 billion, up 39%, and future contracted bookings grew 41% to $15.1 billion. These measures support the view that customers are expanding their use of Axon's devices, cloud software and artificial-intelligence tools.
Growth has not yet removed the valuation risk. The source placed Axon near 9.6 times sales, well above the S&P 500 comparison it used, while trailing operating margin was only 0.7%. Free cash flow was roughly negative $1 million in the second quarter as the company built inventory.
Why the current dip is different
Historical drawdown analysis treats every 20% decline as comparable, but the reasons vary. Some earlier dips occurred during broad market selloffs, while the recent decline followed concern about valuation, cash conversion and a $1 billion zero-coupon convertible-note offering.
The notes provide inexpensive financing and a capped-call hedge can reduce dilution, but the transaction still raises questions about why a fast-growing company needs external capital. Management has targeted about $450 million of full-year free cash flow, making the second-half conversion important.
Axon's revenue and bookings justify attention after a decline. The stronger investment signal would be free cash flow catching up with sales while margins expand. Without that improvement, a history of rebounds says more about past volatility than about the return available from today's valuation.